Genome-wide association studies of antidepressant class response and treatment-resistant depression.

ABSTRACT: The "antidepressant efficacy" survey (AES) was deployed to > 50,000 23andMe, Inc. research participants to investigate the genetic basis of treatment-resistant depression (TRD) and non-treatment-resistant depression (NTRD). Genome-wide association studies (GWAS) were performed, including TRD vs. NTRD, selective serotonin reuptake inhibitor (SSRI) responders vs. non-responders, serotonin-norepinephrine reuptake inhibitor (SNRI) responders vs. non-responders, and norepinephrine-dopamine reuptake inhibitor responders vs. non-responders. Only the SSRI association reached the genome-wide significance threshold (p < 5 × 10^-8): one genomic region in RNF219-AS1 (SNP rs4884091, p = 2.42 × 10^-8, OR = 1.21); this association was also observed in the meta-analysis (13,130 respond

SUBMITTER: Li QS 

PROVIDER: S-EPMC7589471 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature